Supported by an independent educational grant from Pfizer, Inc.
While the evolution of targeted therapies has significantly improved outcomes and quality of life in patients with advanced non-small cell lung cancer (NSCLC), it can be difficult to keep up with recent advances in this field. The Association of Community Cancer Centers (ACCC)—in partnership with the American Society for Clinical Pathology (ASCP)—is committed to ensuring you have the resources, tools, and education you need to optimize the diagnosis, testing, and management of patients with advanced NSCLC, particularly those with ALK mutations.
For more information on this project, please contact the ACCC Provider Education department.
This enduring material was recorded from a half-day, interactive, CME/CMLE-accredited virtual (live) summit to help members of the cancer care team enhance their coordination of patient care and gain deeper scientific knowledge, skills, and competence in biomarker testing practices, treatment selection, and management of adverse events in patients with advanced NSCLC.
Each highly interactive session is presented by an interprofessional faculty team, features rich scenarios and patient cases involving advanced NSCLC, and introduces the patient perspective to address the following topics:
Receive up to 4.5 hours of CME/CMLE credit as you increase your knowledge and competence in the testing, treatment, and management of patients with advanced NSCLC.
Educational activities funded by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer, Inc.
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Biomarkers for Lung Cancer Screening and Detection
Biomarkers in Lung Cancer (first page preview only):
Advances in Treatment of Locally Advanced or Metastatic NSCLC: Targeted Therapyhttps://pubmed.ncbi.nlm.nih.gov/32402358/
ALK Inhibitors for NSCLC: A Systematic Review and Network Meta-Analysis
ALK Inhibitors in the Treatment of ALK-Positive NSCLC
The Safety and Serious Adverse Events of Approved ALK Inhibitors in Malignancies: A Meta-Analysis
Consensus Recommendations for Management and Counseling of Adverse Events Associated with Lorlatinib: A Guide for Healthcare Practitioners
Additional NSCLC Resources from the Association of Community Cancer Centers
Additional resources from ASCP